Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolor Biotech has announced positive top-line results from pilot study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.
Subscribe to our email newsletter
The post-Phase II clinical study data showed that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections of currently marketed human growth hormone.
In the study, 12 patients were switched from daily injections of hGH to a regimen of just two injections of hGH-CTP over a period of one month.
The hGH-CTP two injections contained either 15% or 50% of the total cumulative dose of hGH the patients would usually inject over the 30-day period.
Patient IGF-1 levels were tracked in the study and served as a measure of efficacy, the company said.
Prolor CEO Avri Havron said that the findings from this experiential study are very promising for adult patients in need of growth hormone therapy.
"The results from this new pilot study indicate that hGH-CTP may be able to achieve an even better administration regimen — requiring injections just twice per month," Havron added.